Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 31:16:695-704.
doi: 10.2147/IDR.S393802. eCollection 2023.

Benefits and Safety of Empiric Antibiotic Treatment Active Against KPC- K. pneumoniae in Febrile Neutropenic Patients with Acute Leukemia Who are Colonized with KPC- K. pneumoniae. A 7-Years Retrospective Observational Cohort Study

Alessandra Micozzi  1 , Clara Minotti  2 , Saveria Capria  2 , Claudio Cartoni  2 , Silvia Maria Trisolini  2 , Giovanni Manfredi Assanto  1 , Walter Barberi  2 , Maria Luisa Moleti  2 , Stefania Santilli  3 , Maurizio Martelli  1 , Giuseppe Gentile  1
Affiliations

Benefits and Safety of Empiric Antibiotic Treatment Active Against KPC- K. pneumoniae in Febrile Neutropenic Patients with Acute Leukemia Who are Colonized with KPC- K. pneumoniae. A 7-Years Retrospective Observational Cohort Study

Alessandra Micozzi et al. Infect Drug Resist. .

Abstract

Purpose: To evaluate the benefits and safety of the empiric antibiotic treatment (EAT) active against KPC-K. pneumoniae in febrile neutropenic patients with acute leukaemia (AL) who are colonised by KPC-K. pneumoniae.

Patients and methods: A 7-year (2013-2019) retrospective observational cohort study was conducted at the Haematology, Sapienza Rome University (Italy) on 94 febrile neutropenia episodes (FNE) in AL patients KPC-K. pneumoniae carriers treated with active EAT.

Results: Eighty-two (87%) FNE were empirically treated with antibiotic combinations [38 colistin-based and 44 ceftazidime-avibactam (CAZAVI)-based], 12 with CAZAVI monotherapy. Successful outcomes were observed in 88/94 (94%) FNE, 46/49 (94%) microbiologically documented infections, and 24/27 (89%) gram-negative bloodstream infections (GNB-BSI). Mortality due to infective causes was 4.2% (2.1% within 1 week). KPC-K. pneumoniae infections caused 28/94 FNE (30%) and KPC-K. pneumoniae-BSI was documented in 22 FNE (23.4%) (85% of GNB-BSI), in all cases patients received active EAT, and 21 survived. KPC-K.pneumoniae-BSI mortality rate was 4.5%. CAZAVI-based EAT showed better results than colistin-based EAT (55/56 vs 33/38, p = 0.037), overall and without EAT modification (41/56 vs 20/38, p = 0.02). Empirical combinations including CAZAVI were successful in 98% of cases (43/44 vs 33/38 for colistin-based EAT, p = 0.01), without modifications in 82% (36/44 vs 20/28, p = 0.02). All deaths occurred in patients treated with colistin-based EAT (4/38 vs 0/56, p = 0.02). CAZAVI-containing EAT was the only independent factor for an overall successful response (HR 0.058, CI 0.013-1.072, p = 0.058). Nephrotoxicity occurred in 3(8%) patients undergoing colistin-based EAT (none in those undergoing CAZAVI-based EAT, p = 0.02).

Conclusion: KPC-K. pneumoniae infections are frequent in colonised AL patients with FNE. EAT with active antibiotics, mainly CAZAVI-based combinations, was effective, safe, and associated with low overall and KPC-K. pneumoniae-BSI-related mortality.

Keywords: KPC-K. pneumoniae-BSI mortality rate; ceftazidime-avibactam; colistin; haematological malignancies.

PubMed Disclaimer

Conflict of interest statement

Dr. A. Micozzi and Dr. G. Gentile report support for attending meetings and travelling from Pfizer and Gilead. The other authors report no conflicts of interest in this work.

Similar articles

See all similar articles

Cited by

References

    1. Tofas P, Skiada A, Angelopoulou M, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: analysis of 50 cases. Int J Antimicrob Agents. 2016;47:335–339. doi:10.1016/j.ijantimicag.2016.01.011 - DOI - PubMed
    1. Trecarichi EM, Pagano L, Martino B, et al. Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. Am J Hematol. 2016;91(11):1076–1081. doi:10.1002/ajh.24489 - DOI - PubMed
    1. Poucha SM, Satlin MJ. Carbapenem-resistant Enterobacteriaceae in special populations: solid organ transplant recipients, stem cell transplant recipients, and patients with haematologic malignancies. Virulence. 2017;8:391–402. doi:10.1080/21505594.2016.1213472 - DOI - PMC - PubMed
    1. Micozzi A, Gentile G, Minotti C, et al. Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteraemias. BMC Infect Dis. 2017;17:203. doi:10.1186/s12879-017-2297-9 - DOI - PMC - PubMed
    1. Micozzi A, Gentile G, Santilli S, et al. Reduced mortality from KPC-K. pneumoniae bloodstream infection in high-risk patients with haematological malignancies colonized by KPC-K. pneumoniae. BMC Infect Dis. 2021;21:1079. doi:10.1186/s12879-021-06747-8 - DOI - PMC - PubMed